Autoimmune Diseases  >>  Tavalisse (fostamatinib)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

12 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tavalisse (fostamatinib) / Rigel
OSKIRA -4, NCT01264770 / 2010-023692-26: Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Checkmark OSKIRA 4 (EULAR 2013)
May 2013 - May 2013: OSKIRA 4 (EULAR 2013)
Checkmark OSKIRA-4 P2b results
Dec 2012 - Dec 2012: OSKIRA-4 P2b results
Checkmark P2 data (OSKIRA -4)
More
Terminated
2b
644
US, Canada, Europe, RoW
Fostamatinib and placebo injections, Adalimumab and placebo of fostamatinib, Humira®, Placebo of fostamatinib, fostamatinib, and placebo injections
AstraZeneca
Rheumatoid Arthritis
10/12
08/13
OSKIRA 4 SS, NCT02092961: Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study

Terminated
2b
198
US, Canada, Europe, RoW
Fostamatinib, Adalimumab, Placebo of Fostamatinib, Placebo of Adalimumab
AstraZeneca
Rheumatoid Arthritis
07/13
07/13
NCT00326339: Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1)

Checkmark P2a data: TASKi1 (RA)
Dec 2012 - Dec 2012: P2a data: TASKi1 (RA)
Completed
2
189
US, RoW
R788, tamatinib fosdium, Placebo
Rigel Pharmaceuticals
Rheumatoid Arthritis
10/07
12/07
Taski-3, NCT00665626 / 2008-000743-34: Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis

Checkmark P2 data: TASKi3 (RA)
Dec 2012 - Dec 2012: P2 data: TASKi3 (RA)
Completed
2
219
US, Europe, RoW
Fostamatinib disodium (R935788), Placebo
Rigel Pharmaceuticals
Rheumatoid Arthritis
06/09
06/09
Taski-2, NCT00665925 / 2008-000742-30: Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis

Checkmark P2b data (RA) (Taski-2)
Sep 2012 - Sep 2012: P2b data (RA) (Taski-2)
Completed
2
457
US, Europe, RoW
Fostamatinib disodium (R935788), R935788, Placebo
Rigel Pharmaceuticals
Rheumatoid Arthritis
06/09
06/09
SOLEIL, NCT00752999: Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus

Withdrawn
2
0
US
Fostamatinib Disodium (R935788), R788, Placebo
Rigel Pharmaceuticals
Systemic Lupus Erythematosus
11/09
03/10
NCT00706342: Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)

Completed
2
18
US
Fostamatinib Disodium / R935788, R788
Rigel Pharmaceuticals
Purpura, Thrombocytopenic, Idiopathic
04/10
04/10
NCT01563978 / 2011-006070-73: Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis

Checkmark Rheumatoid arthritis - ACR/ARHP 2013 (OSKIRA-ABPM)
Sep 2013 - Sep 2013: Rheumatoid arthritis - ACR/ARHP 2013 (OSKIRA-ABPM)
Completed
2
266
US, Europe, RoW
fostamatinib, placebo
AstraZeneca
Rheumatoid Arthritis
01/13
01/13
OSKIRA-Asia-1, NCT01569074: Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis

Terminated
2
163
Japan, RoW
Fostamatinib, Placebo
AstraZeneca
Rheumatoid Arthritis
07/13
07/13
OSKIRA-Asia-1X, NCT01640054: A Long Term Study to Assess the Safety of Fostamatinib in Patients in Asia With Rheumatoid Arthritis

Terminated
2
115
Japan, RoW
Fostamatinib
AstraZeneca
Rheumatoid Arthritis
07/13
07/13
NCT00805467 / 2008-000744-13: Open-Label, Multicenter Extension Study for Patients Completing Treatment Phase of a Rigel-Sponsored R935788 Studies

Terminated
2
624
US, Europe, RoW
Fostamatinib Disodium (R935788), R935788
AstraZeneca
Rheumatoid Arthritis
08/13
08/13
NCT02433236: Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy

Withdrawn
2
0
US, Europe, RoW
Fostamatinib Disodium tablet 100 mg, Fostamatinib, R788, Fostamatinib Disodium tablet 150 mg
Rigel Pharmaceuticals
IGA Nephropathy
09/15
 

Download Options